5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Identification of the Factors Associated With Intraperitoneal Pressure in ADPKD Patients Treated With Peritoneal Dialysis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Peritoneal dialysis (PD) is reported to be underused in the autosomal dominant polycystic kidney disease (ADPKD) population because doctors fear technical failure caused by reduced abdominal space and high intraperitoneal pressure (IPP).

          Methods

          We designed a multicenter retrospective study to be carried out in 15 French centers recruiting 60 patients with ADPKD treated with PD to identify factors associated with IPP. Inclusion criteria were start of PD between 2010 and 2017, available tomodensitometry, and IPP measurement in the first year of dialysis. The clinical and radiological data for each patient were reviewed by the same operator. Total kidney volume (TKV), liver volume, and the volume of the abdominal cavity were measured using contouring.

          Results

          TKV and the volume of the abdominal cavity in women and men were, respectively, 2397 ml versus 3758 ml and 9402 ml versus 12,920 ml. In the univariate analysis, IPP was significantly and positively associated with body surface area ( P = 0.0024), body mass index (BMI) ( P < 0.0001), the volume of the abdominal cavity ( P = 0.0005), and the volume of the dialysate infused in the peritoneal cavity (IPV) ( P = 0.0108). In the multivariate analysis, only BMI was still significantly associated with IPP ( P = 0.0004)

          Conclusions

          Our results identified BMI as the main factor linked to IPP in patients with ADPKD. Despite a reliable assessment of the volume of their organs we did not find any correlation between liver and kidney volumes and IPP. To our knowledge, this is the first study designed to identify factors associated with IPP in patients with ADPKD on PD.

          Graphical abstract

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          Autosomal dominant polycystic kidney disease.

          Autosomal dominant polycystic kidney disease is the most prevalent, potentially lethal, monogenic disorder. It is associated with large interfamilial and intrafamilial variability, which can be explained to a large extent by its genetic heterogeneity and modifier genes. An increased understanding of the disorder's underlying genetic, molecular, and cellular mechanisms and a better appreciation of its progression and systemic manifestations have laid out the foundation for the development of clinical trials and potentially effective treatments.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Clinical practice. Autosomal dominant polycystic kidney disease.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Prevalence of autosomal dominant polycystic kidney disease in the European Union

              Abstract Background Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease, but estimates of its prevalence vary by >10-fold. The objective of this study was to examine the public health impact of ADPKD in the European Union (EU) by estimating minimum prevalence (point prevalence of known cases) and screening prevalence (minimum prevalence plus cases expected after population-based screening). Methods A review of the epidemiology literature from January 1980 to February 2015 identified population-based studies that met criteria for methodological quality. These examined large German and British populations, providing direct estimates of minimum prevalence and screening prevalence. In a second approach, patients from the 2012 European Renal Association‒European Dialysis and Transplant Association (ERA–EDTA) Registry and literature-based inflation factors that adjust for disease severity and screening yield were used to estimate prevalence across 19 EU countries (N = 407 million). Results Population-based studies yielded minimum prevalences of 2.41 and 3.89/10 000, respectively, and corresponding estimates of screening prevalences of 3.3 and 4.6/10 000. A close correspondence existed between estimates in countries where both direct and registry-derived methods were compared, which supports the validity of the registry-based approach. Using the registry-derived method, the minimum prevalence was 3.29/10 000 (95% confidence interval 3.27–3.30), and if ADPKD screening was implemented in all countries, the expected prevalence was 3.96/10 000 (3.94–3.98). Conclusions ERA–EDTA-based prevalence estimates and application of a uniform definition of prevalence to population-based studies consistently indicate that the ADPKD point prevalence is <5/10 000, the threshold for rare disease in the EU.
                Bookmark

                Author and article information

                Contributors
                Journal
                Kidney Int Rep
                Kidney Int Rep
                Kidney International Reports
                Elsevier
                2468-0249
                29 April 2020
                July 2020
                29 April 2020
                : 5
                : 7
                : 1007-1013
                Affiliations
                [1 ]Division of Nephrology, University Hospital of Reims, Reims, France
                [2 ]Division of Nephrology, University Hospital of Angers, Angers, France
                [3 ]Division of Nephrology, Hospital of Le Mans, Le Mans, France
                [4 ]Clinical Investigation Center, University Hospital of Reims, Reims, France
                [5 ]Division of Nephrology, University Hospital of Strasbourg, Strasbourg, France
                [6 ]Nephrology Laboratory, Unit 7369, Matrice Extracellulaire et Dynamique Cellulaire, MEDyC, Reims Champagne Ardenne University, Reims, France
                Author notes
                [] Correspondence: Mickael Sigogne, Service de Néphrologie-Dialyse-Transplantation, CHU d’Angers, 49933 Angers Cedex 9, France. Mickael.Sigogne@ 123456chu-angers.fr
                Article
                S2468-0249(20)31211-0
                10.1016/j.ekir.2020.04.012
                7335974
                32647758
                61a0217d-c6bf-43a5-bf46-0c702fab32b1
                © 2020 International Society of Nephrology. Published by Elsevier Inc.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 17 July 2019
                : 6 April 2020
                : 13 April 2020
                Categories
                Clinical Research

                adpkd,intraperitoneal pressure,peritoneal dialysis
                adpkd, intraperitoneal pressure, peritoneal dialysis

                Comments

                Comment on this article